surmount-1 tirzepatide trial obesity without diabetes after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 SURMOUNT 1 // Three-Year Obesty

A There are no specific manufacturer recommendations

How Long Until I Notice Results

1985, Geneva: WHO Waterlow JC: Whole-body protein turnover in humans past, present, and future

Monitoring requirements Qsymia requires more routine monitoring than GLP-1 medications: Monthly pregnancy tests for women of childbearing age Regular heart rate monitoring Periodic blood work for bicarbonate levels (metabolic acidosis screening) Kidney function tests Mood and cognition assessment GLP-1 medications generally require less intensive monitoring, though periodic blood work to check pancreatic enzymes and kidney function is still recommended

8 GLP-1 RAs and DR: What the data show The CDCs Vision and Eye Health Surveillance System estimated that in 2021, there were 9.6 million people (26 percent of those with diabetes) living with diabetic retinopathy in the United States and among them, 1.84 million people (5 percent) living with vision-threatening diabetic retinopathy